scholarly journals Efficacy and Safety of Topical 3% Diquafosol Ophthalmic Solution for the Treatment of Multifactorial Dry Eye Disease: Meta-Analysis of Randomized Clinical Trials

2019 ◽  
Vol 61 (4) ◽  
pp. 188-198 ◽  
Author(s):  
Kiyeun Nam ◽  
Hyun Jung Kim ◽  
Aeri Yoo
Keyword(s):  
Clinical Trials ◽  
Dry Eye ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Ophthalmic Solution ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Efficacy And Safety ◽  
Diquafosol Ophthalmic Solution

scholarly journals Effects of Polyunsaturated Fatty Acids on Nonspecific Typical Dry Eye Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Nutrients ◽  
2019 ◽  
Vol 11 (5) ◽  
pp. 942 ◽  
Author(s):  
Sheng-Chu Chi ◽  
Hsin-I Tuan ◽  
Yi-No Kang
Keyword(s):  
Fatty Acids ◽  
Clinical Trials ◽  
Polyunsaturated Fatty Acids ◽  
Dry Eye ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Dry Eye Disease ◽  
Cochrane Library ◽  
Eye Disease ◽  
Short Term Treatment

To investigate the effects of polyunsaturated fatty acids (PUFAs) in patients with dry eye disease (DED), a multifactorial inflammatory disorder, we searched Cochrane Library, EMBASE, PubMed, and Web of Science for randomized clinical trials (RCTs) investigating the effect of PUFAs in patients with DED before March 2019. Two reviewers independently abstracted data of tear breakup time (TBUT), Schirmer’s test, osmolarity, and ocular surface disease index (OSDI). We conducted pairwise meta-analysis using means and standard deviations (SDs) in a random-effects model for continuous outcomes. Thirteen eligible RCTs with 1782 patients with nonspecific typical DED were included. Patients who received PUFA treatment without other eye medications exhibited greater improvements in TBUT (MD = 1.80; p = 0.001), Schirmer test scores (MD = 0.50; p < 0.001), osmolarity (MD = −15.95; p < 0.001), and OSDI scores (MD = −10.19; p < 0.001) than those who received placebo treatment. However, the effects of PUFAs on TBUT (p < 0.001) and OSDI scores (p = 0.03) weakened with treatment duration. PUFAs are effective in treating nonspecific typical DED, particularly as a short-term treatment, with relatively few adverse events. Therefore, in real-world clinical practice, PUFA supplements are worth being suggested to patients with nonspecific typical DED who are not concurrently using other topical or systematic eye medications.

scholarly journals Corrigendum: The Efficacy and Safety of Qiming Granule for Dry Eye Disease: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 11 ◽  
Author(s):  
Maoyi Yang ◽  
Zhipeng Hu ◽  
Rensong Yue ◽  
Liangjun Yang ◽  
Boxun Zhang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Dry Eye ◽  
Meta Analysis ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Efficacy And Safety

scholarly journals The Efficacy and Safety of Qiming Granule for Dry Eye Disease: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 11 ◽  
Author(s):  
Maoyi Yang ◽  
Zhipeng Hu ◽  
Rensong Yue ◽  
Liangjun Yang ◽  
Boxun Zhang ◽  
...  
Keyword(s):  
Dry Eye ◽  
Meta Analysis ◽  
Tear Film ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Efficacy And Safety ◽  
Chinese Patent ◽  
Traditional Chinese Patent Medicine ◽  
Positive Results

BackgroundDry eye disease (DED) is a common complication in clinical practice. Qiming granule, a traditional Chinese patent medicine, is widely used in treating DED in China. However, its effect is still largely unknown.ObjectivesThis research aims to evaluate the efficacy and safety of QG on DED.MethodsThree English database and four Chinese databases without restriction on language and publication bias were searched. Qualified literature was selecting according to inclusion and exclusion criteria, extracted the data, and conducted a meta-analysis.ResultsA total of 11 articles were included in this meta-analysis. The methodological quality of included studies was low. The results showed that QG was effective for DED (RR:1.26, 95%CI:1.12 to 1.41, P=0.0001). The results combined with random effects model showed that QG could significantly prolong the tear film break up time (MD: 2.93, 95% CI: 2.22 to 3.65, P &lt; 0.00001), increase the amount of tears in patients with DED (MD: 2.94, 95% CI: 1.83 to 4.04, P &lt; 0.00001) and repair the corneal defects in patients (MD: -0.71, 95% CI: -1.25 to -0.17, P &lt; 0.00001).ConclusionsThis study found that despite of the apparently positive results of some outcomes, it is premature to confirm the efficacy of QG in treating DED. More high-quality studies are still needed in the future to further confirm the efficacy and safety.

scholarly journals Clinical effectiveness of diquafosol ophthalmic solution 3% in Korean patients with dry eye disease: a multicenter prospective observational study

2021 ◽  
Vol 14 (10) ◽  
pp. 1518-1526
Author(s):  
Youngsub Eom ◽  
Keyword(s):  
Dry Eye ◽  
Ophthalmic Solution ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Dependent Manner ◽  
Subjective Symptoms ◽  
Korean Patients ◽  
Staining Score ◽  
Switch Group ◽  
Diquafosol Ophthalmic Solution

AIM: To investigate the effectiveness of diquafosol ophthalmic solution 3% administered in Korean patients with dry eye disease in real-world clinical settings. METHODS: Diquafosol was administered for 8wk to 3 patient groups who received diquafosol as add-on therapy to existing medication (Add group, n=150); received diquafosol only (Monotherapy group, n=196); or discontinued part of their existing medication in favor of diquafosol (Switch group, n=11). Tear break-up time (TBUT), cornea and conjunctival staining based on National Eye Institute/Industry scoring scheme, subjective symptoms using the Ocular Surface Disease Index (OSDI) questionnaire, and meibum quality and expressibility were evaluated at baseline, week 4, and week 8. RESULTS: The mean TBUT increased (from 3.46, 3.92, and 5.84s, respectively, to 5.15, 5.53, and 8.59s, respectively) and corneal staining score decreased (from 2.23, 2.24, and 3.09, respectively, to 0.85, 0.97, and 1.64, respectively) in a time-dependent manner from baseline to week 8 in all three groups. Conjunctival staining score, OSDI questionnaire, and meibum quality and expressibility improved over time from baseline to week 8 in the Add and Monotherapy groups, but differences were not statistically significant in the Switch group. CONCLUSION: Diquafosol improves subjective symptoms and objective signs in patients treated with existing medicines combined with diquafosol and treated solely with diquafosol. Diquafosol can be used as an effective therapeutic agent for dry eye disease or additionally applied in patients who have insufficient response to existing medicines.

scholarly journals Lifitegrast: a novel drug for patients with dry eye disease

2019 ◽  
Vol 11 ◽  
pp. 251584141987036 ◽  
Author(s):  
Stacy L. Haber ◽  
Vera Benson ◽  
Casey J. Buckway ◽  
Jennifer M. Gonzales ◽  
David Romanet ◽  
...  
Keyword(s):  
Dry Eye ◽  
English Language ◽  
Ophthalmic Solution ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Inadequate Response ◽  
Efficacy And Safety ◽  
Inclusion Phase

The objective of this article is to review the pharmacology, efficacy, and safety of lifitegrast and determine its role relative to other agents in the management of dry eye disease. A PubMed search (1946 to December 2018) using the terms lifitegrast and SAR 1118 was conducted to identify relevant articles. In vitro or in vivo evaluations of lifitegrast published in the English language were eligible for inclusion. Phase II and III trials were selected for review of efficacy and safety. Four randomized controlled trials evaluated the efficacy and safety of lifitegrast 0.5% ophthalmic solution for 12 weeks, and 1 additional trial assessed safety for 1 year. In a majority of the trials, lifitegrast caused statistically significant improvements in inferior corneal fluorescein staining scores and eye dryness scores. The most common adverse effects were eye irritation, dysgeusia, and reduced visual acuity, and most were mild to moderate in severity. Lifitegrast has a novel mechanism of action and is safe and effective for the treatment of dry eye disease. At this time, lifitegrast may be considered as an option for patients who have an inadequate response to artificial tears.

Oxidative and antioxidative stress markers in dry eye disease: A systematic review and meta‐analysis

2021 ◽  
Author(s):  
Valentin Navel ◽  
Vincent Sapin ◽  
Fanny Henrioux ◽  
Loïc Blanchon ◽  
Antoine Labbé ◽  
...  
Keyword(s):  
Systematic Review ◽  
Dry Eye ◽  
Meta Analysis ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Stress Markers ◽  
Antioxidative Stress

scholarly journals Characterization of tear production in subjects with dry eye disease during intranasal tear neurostimulation: Results from two pivotal clinical trials

2019 ◽  
Vol 17 (1) ◽  
pp. 142-150 ◽  
Author(s):  
John D. Sheppard ◽  
Gail L. Torkildsen ◽  
Joel A. Geffin ◽  
Jung Dao ◽  
David G. Evans ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Dry Eye ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Tear Production

Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials

2017 ◽  
Vol 43 (1) ◽  
pp. 48-58 ◽  
Author(s):  
M.B. Rehman ◽  
B.V. Tudrej ◽  
J. Soustre ◽  
M. Buisson ◽  
P. Archambault ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Efficacy And Safety
Sign in / Sign up

Export Citation Format

Share Document